bronchial asthma is a common chronic respiratory disease, characterized by chronic respiratory inflammation, high-reactive and reversible air flow limitations. While bronchial asthma is not primarily caused by infection, in some cases it may induce or exacerbate asthma symptoms. It is therefore important to understand the principles and experience of bronchial asthma treatment for infections.
Principles of treatment
1. Identifying the causes of infection – Before considering anti-infection treatment, the existence of the infection and its pathogens need to be identified. The type of infection and the pathogen are judged through clinical performance, laboratory tests (e.g., blood protocol, C reaction protein, stinging, etc.) in order to select the appropriate anti-infection drugs.
2. Individualized treatment – Individualized anti-infection treatment programmes based on the severity of the patient ‘ s condition, age, underlying illness, history of drug allergy, etc. Anti-infection treatment may not be needed for persons with mild asthma; and anti-infection treatment should be provided in a timely manner for patients with severe asthma attacks with visible signs of infection.
3. Avoid overuse of antibiotics – As bronchial asthma is mainly a respiratory inflammation caused by non-infective factors, overuse of antibiotics not only does not alleviate asthma symptoms, but may also lead to an increase in bacterial resistance and adverse reactions. Therefore, antibiotics should not be used blindly without clear evidence of infection.
II. Sharing of experiences
1. Virus infection – Virus infection is one of the common causes of bronchial asthma. Antibiotic treatment is not generally recommended for asthma attacks caused by viral infections. Treatment is mainly provided for cases of asthma, such as the use of bronchial expansionants and the inhalation of sugar cortex hormones. At the same time, attention is paid to rest, drinking water and enhancing the immune capacity of the body.
Bacteria infections – When bacterial infections are suspected, sensitive antibiotics should be selected on the basis of stinging and drug-sensitive tests. If there are no conditions for training, antibiotics can be selected on the basis of clinical experience. For mild bacterial infections, oral antibiotics can be selected and intravenous drugs can be considered for patients with severe infections or with poor oral treatment. – Antibiotics commonly used for bronchial asthma combined bacterial infections, such as Amosilin/Klaveic acid, headgillactin, large ringed esters, etc. In the use of antibiotics, care is taken to observe the adverse effects of drugs, such as allergies, gastrointestinal responses, etc.
Fungi infections – fungi infections occur when bronchial asthma patients use immunosuppressants such as sugar-coated hormones on a permanent basis. The diagnosis of fungi infections is difficult and requires a combination of clinical performance, fungi culture, seroscopy, etc. Once detected as fungi infection, suitable antifluorinated drugs, such as fluoride, Ecraconol, etc., should be selected according to the fungi type.
4. Joint treatment – bronchial expansion agents, inhalation of sugary cortex hormones, and asthma treatments should continue to be provided in conjunction with anti-infection treatment to control asthma symptoms. In the case of persons with severe asthma, joint use of antibiotics and glucose hormonal intravenous drips could be considered to improve treatment effectiveness.
In short, bronchial asthma anti-infection treatment needs to follow the principles of clear cause, individualized treatment and avoidance of overuse of antibiotics. In the course of treatment, appropriate anti-infection drugs are selected on a patient-specific basis and combined with regular asthma treatment to control asthma symptoms and prevent relapse. At the same time, strengthening patients ‘ health education and raising their awareness of asthma and self-management capabilities are important measures to prevent asthma and infection.
